Molecular Formula | C30H53N3O6 |
Molar Mass | 551.75832 |
Melting Point | 72-75?C |
Boling Point | 748.4°C at 760 mmHg |
Flash Point | 406.4°C |
Solubility | Methanol (Slightly), Water (Slightly) |
Vapor Presure | 1.59E-23mmHg at 25°C |
Appearance | Solid |
Color | White |
Storage Condition | Sealed in dry,Store in freezer, under -20°C |
Sensitive | Sensitive to heat and light |
In vitro study | Aliskiren hemifumarate appears to bind to the hydrophobic S1/s3-binding pocket and to a large, distinct subpocket extending from the s3-binding site to the hydrophobic core of renin. The oral availability of Aliskiren hemifumarate is 2.4, 16, and 2.5 in rats, marmosets, and humans, respectively. |
In vivo study | In sodium-depleted marmosets, Aliskiren hemifumarate (< 10 mg/kg, oral) inhibits plasma renin activity and lowers blood pressure. In patients with mild to moderate hypertension, once-daily oral treatment with Aliskiren hemifumarate is effective in lowering blood pressure and is safe and tolerable. |